Início › Mieloma Múltiplo › Distrito de Columbia › Washington
Ensaios clínicos de Mieloma Múltiplo em Washington, DC
22 estudos para Mieloma Múltiplo estão buscando participantes em locais em Washington e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecrutandoFase 1
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecrutandoFase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecrutandoEstudo observacional
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RecrutandoFase 2
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
Tissue Collection for Studies of Lymph Cancer
RecrutandoEstudo observacional
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RecrutandoFase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · a 7 mi de distância
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecrutandoFase 3
- Center for Cancer and Blood Disorders, Bethesda · a 7 mi de distância
18F-Fluciclovine PET/CT in Multiple Myeloma
RecrutandoFase 2
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecrutandoFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · a 7 mi de distância
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
RecrutandoFase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
RecrutandoEstudo observacional
- National Institutes of Health Clinical Center, Bethesda · a 7 mi de distância
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RecrutandoFase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RecrutandoFase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
RecrutandoFase 2
- GSK Investigational Site, Bethesda · a 7 mi de distância
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecrutandoFase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Recrutando
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecrutandoFase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · a 7 mi de distância
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RecrutandoFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · a 7 mi de distância
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecrutandoFase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RecrutandoFase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecrutandoFase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Ensaios de Mieloma Múltiplo em outras cidades
- New York City, NY60 estudos
- Atlanta, GA42 estudos
- Boston, MA42 estudos
- Houston, TX38 estudos
- Durham, NC37 estudos
- Nashville, TN32 estudos
- Denver, CO27 estudos
- Rochester, MN24 estudos
- St. Louis, MO24 estudos
- Columbus, OH24 estudos
- Baldwin Park, CA23 estudos
- Chicago, IL22 estudos
Outros estudos em Washington
- Câncer (todos os tipos)58 estudos
- Câncer de Pulmão de Não Pequenas Células55 estudos
- Câncer de Mama46 estudos
- Câncer Metastático43 estudos
- Câncer de Pulmão41 estudos
- Câncer de Próstata38 estudos
- Obesidade33 estudos
- Câncer Colorretal29 estudos
- Doença Cardiovascular28 estudos
- Câncer de Bexiga26 estudos
- Leucemia Mieloide Aguda24 estudos
- Câncer de Ovário23 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.